These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36160021)

  • 1. Comparison of effectiveness and safety of camrelizumab between HBV-related and non-B, non-C hepatocellular carcinoma: A retrospective study in China.
    Liu H; Qin X; Xu Z; Wu M; Lu T; Zhou S; Yao N; Liu S; Shao Y; Han Z
    Front Genet; 2022; 13():1000448. PubMed ID: 36160021
    [No Abstract]   [Full Text] [Related]  

  • 2. Transarterial Chemoembolization plus Apatinib with or without Camrelizumab for the Treatment of Advanced HBV-related Hepatocellular Carcinoma.
    Liu H; Yu Q; Gu T; Qu P; Ma X; Zhou S; Lu T; Pan D; Han Z
    J Gastrointestin Liver Dis; 2023 Jun; 32(2):182-189. PubMed ID: 37345608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and non-B non-C hepatocellular carcinoma: a nationwide study of 11,950 patients.
    Utsunomiya T; Shimada M; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Takayama T; Kokudo N;
    Ann Surg; 2015 Mar; 261(3):513-20. PubMed ID: 25072437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative Outcomes for Patients with Non-B Non-C Hepatocellular Carcinoma: A Subgroup Analysis of Patients with a History of Hepatitis B Infection.
    Omichi K; Shindoh J; Yamamoto S; Matsuyama Y; Akamatsu N; Arita J; Kaneko J; Sakamoto Y; Hasegawa K; Kokudo N
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1034-40. PubMed ID: 26350363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis.
    Yu B; Zhi X; Li Q; Li T; Chen Z
    BMC Gastroenterol; 2023 Aug; 23(1):289. PubMed ID: 37612653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.
    Pan D; Liu HN; Yao ZY; Chen XX; Li YQ; Zhu JJ; Han ZX; Qin XB
    World J Gastrointest Oncol; 2024 Jun; 16(6):2504-2519. PubMed ID: 38994160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.
    Li T; Guo J; Liu Y; Du Z; Guo Z; Fan Y; Cheng L; Zhang Y; Gao X; Zhao Y; He X; Wu W; Gao N; Wu Y; Li J; Zhang Y; Kang W; Cai Z; Wang W; Li X; Zan Y; Nguyen MH; Ji F
    Cancer Immunol Immunother; 2023 Jul; 72(7):2137-2149. PubMed ID: 36840762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment outcomes after radiofrequency ablation in patients with non-B non-C hepatocellular carcinoma within Milan criteria: comparison with HBV-related hepatocellular carcinoma.
    Liu B; Tan Y; Shen H; Wang L; Huang G; Huang T; Long H; Xie X; Xie X
    Int J Hyperthermia; 2023; 40(1):2244207. PubMed ID: 37580046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy.
    Li X; Wang J; Ding X; Xu Y; Yu M; Wu H; Deng N; Li W; Chen J
    Front Pharmacol; 2022; 13():1032881. PubMed ID: 36703739
    [No Abstract]   [Full Text] [Related]  

  • 10. Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients.
    Chen J; Hu X; Li Q; Dai W; Cheng X; Huang W; Yu W; Chen M; Guo Y; Yuan G
    Ann Transl Med; 2020 Sep; 8(18):1187. PubMed ID: 33241036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes after curative hepatectomy in patients with non-B non-C hepatocellular carcinoma and hepatitis B virus hepatocellular carcinoma from non-cirrhotic liver.
    Kim JM; Kwon CH; Joh JW; Park JB; Lee JH; Kim SJ; Paik SW; Park CK; Yoo BC
    J Surg Oncol; 2014 Dec; 110(8):976-81. PubMed ID: 25171344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clinical features and outcomes between HBV-related and non-B non-C hepatocellular carcinoma.
    Xue X; Liao W; Xing Y
    Infect Agent Cancer; 2020; 15():11. PubMed ID: 32082414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study.
    Wei F; Huang Q; He J; Luo L; Zeng Y
    Cancer Manag Res; 2021; 13():4233-4240. PubMed ID: 34079375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma.
    Wakiyama S; Matsumoto M; Haruki K; Gocho T; Sakamoto T; Shiba H; Futagawa Y; Ishida Y; Yanaga K
    Anticancer Res; 2017 Jun; 37(6):3207-3213. PubMed ID: 28551666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma.
    Wu SS; Shan QY; Xie WX; Chen B; Huang Y; Guo Y; Xie XY; Lu MD; Peng BG; Kuang M; Shen SL; Wang W
    Clin Transl Oncol; 2020 Mar; 22(3):401-410. PubMed ID: 31172445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center.
    Ju S; Zhou C; Yang C; Wang C; Liu J; Wang Y; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    Front Oncol; 2021; 11():835889. PubMed ID: 35174073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C.
    Hsu PY; Hsu CT; Yeh ML; Huang CF; Huang CI; Liang PC; Lin YH; Hsieh MY; Wei YJ; Hsieh MH; Dai CY; Lin ZY; Chen SC; Huang JF; Yu ML; Chuang WL
    Dig Dis Sci; 2020 Jul; 65(7):2120-2129. PubMed ID: 31722058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma.
    Liu Q; Li F; Zhuang Y; Xu J; Wang J; Mao X; Zhang Y; Liu X
    Gut Pathog; 2019; 11():1. PubMed ID: 30675188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and potential aetiologies of non-B non-C hepatocellular carcinoma in hepatitis B virus endemic area.
    Lee SB; Kim KM; An J; Lee D; Shim JH; Lim YS; Lee HC; Chung YH; Lee YS
    Liver Int; 2016 Sep; 36(9):1351-61. PubMed ID: 26913702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.